Group of people in front of rainbow flag

Cytomegalovirus (CMV) infection is common in people living with HIV and may contribute to chronic inflammation, which is greater in people with HIV than in people without HIV. This study (A5383) is testing a drug called letermovir that targets CMV. It will see if letermovir reduces levels of inflammation measured in blood in adults living with HIV and CMV.

Eligibility:

  •  ≥ 40 years of age
  • HIV positive and evidence of prior CMV exposure (study will perform the test for CMV)
  • On continuous HIV treatment for at least 48 weeks
  • Undetectable viral load for at least 48 weeks

For more information about A5383, please contact our study team at 310-843-2015 or CAREOUTREACH@mednet.ucla.edu.